All In Biotech

Drug Trial Radar · NCT04802057

Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088

An Open-label, Long-term, Safety and Tolerability Study of SAR445088 in Participants With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088

Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

9

Actual

Start

Mar 22, 2021

Primary completion

Mar 4, 2025

Study completion Mar 4, 2025

Sponsor

Lead sponsor
Bioverativ, a Sanofi companySanofi (SNY)
Sponsor type
Industry
First posted
Mar 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To assess the long-term safety and tolerability in patients with cold agglutinin disease (CAD), after multiple doses of SAR445088 Secondary Objective: To assess, in patients with cold agglutinin disease (CAD), after multiple doses of SAR445088: * The long-term effect of SAR445088 on complement mediated hemolysis * The long-term pharmacodynamics (PD) effect of SAR445088 relating to complement inhibition * The long-term pharmacokinetic (PK) profile of SAR445088 * The long-term immunogenicity of SAR445088

Conditions

  • Autoimmune Haemolytic Anaemia

Interventions

  • SAR445088Drug

    Pharmaceutical form: solution for injection Route of administration: IV and SC (Part 1) IV (Part 2)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse events (TEAE)Time frame: Day 1 or Day 1-IV to end of study, approximately 6 years

Locations

5 sites in 5 countries. Site status is shown where the registry gives one.

  • Investigational Site Number : 2760001

    Essen, Germany

  • Investigational Site Number : 3800001

    Milan, Milano, Italy

  • Investigational Site Number : 5280001

    Amsterdam, Netherlands

  • Investigational Site Number : 5780001

    Bergen, Norway

  • Investigational Site Number : 8260001

    London, London, City of, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.